CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Here, by considering a prospective pilot cohort of treatment withdrawal, we compared non-relapsed and relapsed CML patients during the first year following treatment cessation, in a comprehensive study of innate CD8 T-cells, along with iNKT and γδ T-cells, and NK cells, as a reference for innate immune signature of TFR, in terms of relative frequency and functional profile.